Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Total Liabilities (2022 - 2025)

Gossamer Bio (GOSS) has 4 years of Total Liabilities data on record, last reported at $291.2 million in Q3 2025.

  • For Q3 2025, Total Liabilities fell 1.88% year-over-year to $291.2 million; the TTM value through Sep 2025 reached $291.2 million, down 1.88%, while the annual FY2024 figure was $285.8 million, 14.71% up from the prior year.
  • Total Liabilities reached $291.2 million in Q3 2025 per GOSS's latest filing, up from $287.0 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $296.7 million in Q3 2024 and bottomed at $232.6 million in Q1 2024.
  • Average Total Liabilities over 4 years is $267.5 million, with a median of $264.5 million recorded in 2022.
  • Peak YoY movement for Total Liabilities: fell 8.94% in 2023, then grew 23.3% in 2025.
  • A 4-year view of Total Liabilities shows it stood at $260.4 million in 2022, then dropped by 4.31% to $249.1 million in 2023, then rose by 14.71% to $285.8 million in 2024, then grew by 1.87% to $291.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $291.2 million in Q3 2025, $287.0 million in Q2 2025, and $286.8 million in Q1 2025.